Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Tetracyclic CDK9 kinase inhibitors

Tetracyclic CDK9 kinase inhibitors

US Patent 9328112 · Granted May 3, 2016

Estimated economic value: $240,315,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibi2024
Modulators of the integrated stress pathway2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune 2024
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune 2023
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune 2023
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune 2023
Anti-EGFR antibody-drug conjugates2023
Recombinant human replication-deficient adenovirus comprising a modified nucleic2022
Prodrug modulators of the integrated stress pathway2021
Modulators of the integrated stress pathway2021
Modulators of the integrated stress pathway2020